News

Current News in Drug Discovery

Nature Reviews Drug Discovery

Integrating QSAR modelling and deep learning in drug discovery: the emergence of deep QSAR December 8, 2023
Nature Reviews Drug Discovery, Published online: 08 December 2023; doi:10.1038/s41573-023-00832-0Advances with deep learning, the growth of databases of molecules for virtual screening and improvements in computational power have supported the emergence of a new field of quantitative structure–activity relationship (QSAR) modelling applications that Tropsha et al. term ‘deep QSAR’. This article discusses key advances in […]
Alexander Tropsha
Upcoming market catalysts in Q1 2024 December 7, 2023
Nature Reviews Drug Discovery, Published online: 07 December 2023; doi:10.1038/d41573-023-00191-wUpcoming market catalysts in Q1 2024
Zhyar Said
Top product forecasts for 2024 December 7, 2023
Nature Reviews Drug Discovery, Published online: 07 December 2023; doi:10.1038/d41573-023-00198-3Top product forecasts for 2024
Paul Verdin
Extracellular targeted protein degradation: an emerging modality for drug discovery December 7, 2023
Nature Reviews Drug Discovery, Published online: 07 December 2023; doi:10.1038/s41573-023-00833-zA diverse range of systems have recently been developed to promote the degradation of extracellular and membrane protein targets by using bispecific antibodies, conjugates or small molecules to traffic targeted proteins to the lysosome. This article describes and categorizes systems for extracellular targeted protein degradation, including […]
James A. Wells
De-risking rare disease acquisitions: a win–win–win for patients, biotech and investors December 6, 2023
Nature Reviews Drug Discovery, Published online: 06 December 2023; doi:10.1038/d41573-023-00190-xDe-risking rare disease acquisitions: a win–win–win for patients, biotech and investors
James A. Levine
γ-secretase inhibitor notches first approval December 6, 2023
Nature Reviews Drug Discovery, Published online: 06 December 2023; doi:10.1038/d41573-023-00204-8γ-secretase inhibitor notches first approval
Katie Kingwell
Antibodies achieve leptin balancing act December 6, 2023
Nature Reviews Drug Discovery, Published online: 06 December 2023; doi:10.1038/d41573-023-00203-9Antibodies achieve leptin balancing act
M. Teresa Villanueva
A decade of HCV drugs December 6, 2023
Nature Reviews Drug Discovery, Published online: 06 December 2023; doi:10.1038/d41573-023-00200-yA decade of HCV drugs
Asher Mullard

Vitreon America™ Launches Botanicopeia™ Database and Federal Government Services at NIH Festival+

BETHESDA, MD, September 17, 2016 − Vitreon America, Inc.^™ participated this week in the National Institute of Health (NIH) Intramural Research Program’s 30^th Annual NIH Research Festival which was held September 15-16, 2016 at the NIH Bethesda, Maryland campus.

The Festival included plenary sessions, symposia, exhibits, poster sessions and tours designed to encourage sharing and learning about the exciting research taking place on NIH campus.

Vitreon America^™ was selected by the Technical Sales Association (TSA) which sponsors the Research Festival Exhibit, to launch its state-of-the-art Phytochemical and Ethnobotanical database subscription services, Botanicopeia^™.

Attending on behalf of Vitreon America^™
were Michael Megginson, VP of Business Development (left) and Jorgen Sandberg,
CEO (right).

Vitreon America was pleased to see the interest from the NIH Institutions to utilize the Botanicopeia^™ database subscriptions with many NIH researchers expressing interest in considering the Vitreon America Botanical Research Analytic services as well to optimize the Botanicopeia^™ database.

Based on the NIH researchers feedback, Vitreon America has established a Botanicopeia^™ database subscription service agreement and subscription service with botanical research analytic services through Marshall Communications Corporation, www.marshallcomm.com.

Vitreon America services are available through Marshall Communications Corporation (VOSB) on NIH’s Information Technology Acquisition and Assessment Center’s (NITAAC)- Government-wide Acquisition Contract (GWAC) vehicle. [Prime Contract Holder #HHSN316201500063W]

Vitreon America^™ was established with the goal of commercializing their Botanicopeia^™ database and botanical research analytic services for development of botanicals and phytochemicals in the creation of new medicinal products by Vitreon America Clients.

To find out more about our Services please contact us for assistance at 1-888-214-2584 or at info@vitreonamerica.com

About Vitreon America™

Vitreon America^TM was formed with the goal of disseminating their Botanicopeia^TM database to encourage the increased use of botanicals and phytochemicals in the creation of new medicines.

Contact Vitreon America, Inc.

Vitreon America Botanical Research Center @ Hopkins Johns Hopkins University

MCC 9601 Medical Center Drive, Suite 221
Rockville, Maryland 20850

+1-888-214-2584

j.shaver@advasur.com